Skip to main content
  • ADRIFT Finds Low-Dose Rivaroxaban Superior to DAPT for Controlling Thrombin Generation After LAA Closure in AFib Patients

    The ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Treated with Left Atrial Appendage Closure) study, presented Monday at the European Society of Cardiology Congress 2019 by Gilles Montalescot, MD, PhD, demonstrated that a reduced dose of rivaroxaban alone is superior to dual-antiplatelet therapy in controlling thrombin generation (coagulable state).

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details